Every Form 4 that scPharmaceuticals Inc. (SCPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SCPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCPH filings page.
scPharmaceuticals insider transactions tied to merger consideration: The reporting person, Leonard D. Schaeffer, reported that on 10/07/2025 non‑derivative holdings totaling 111,900 shares were disposed (68,796 direct; 43,104 indirect) in connection with a completed tender offer and merger. Tendering shareholders received $5.35 per share in cash plus one non‑tradable contingent value right (CVR) that may pay up to $1.00 per CVR upon achievement of specified regulatory and net‑sales milestones. Outstanding stock options with exercise prices below $5.35 were cancelled and converted into cash payments and one CVR per underlying share; the reporting person’s affected options totaling 66,050 (30,000; 19,750; 16,300) were reported as disposed.
scPharmaceuticals Inc. (SCPH) Form 4 filed for director Klaus R. Veitinger reports changes tied to a merger transaction completed on 10/07/2025. Pursuant to an Agreement and Plan of Merger with MannKind Corporation, a tender offer and related merger mechanics caused all outstanding company options with an exercise price below $5.35 to be cancelled and converted. Four option grants exercisable for a total of 72,174 underlying shares were cancelled: 30,000 @ $3.85, 19,750 @ $4.11, 16,300 @ $4.53, and 6,124 @ $3.37. Each cancelled option holder will receive cash equal to the excess of $5.35 over the option exercise price multiplied by the number of shares, plus one contingent value right (CVR) per share, subject to withholding.
Insider report summary: A Form 4 filed for Abraham William Tober, a director of scPharmaceuticals Inc. (SCPH), discloses cancellation of multiple outstanding stock options and conversion mechanics tied to a merger with MannKind Corporation. On 10/07/2025 the reporting person had three option grants cancelled and treated as dispositions: 30,000, 19,750, and 16,300 option shares. Under the Merger Agreement, Company Options with exercise prices below $5.35 were cancelled and converted into (i) a cash payment equal to the excess of $5.35 over the option exercise price times the number of shares and (ii) one contingent value right per share.
The Form 4 lists the options as disposed (Transaction Code D) on 10/07/2025 and shows 0 shares of common stock resulting from these specific derivative holdings after the transactions.
scPharmaceuticals Inc. (SCPH) reported that on 10/07/2025 a reporting person canceled a set of stock options in connection with a completed tender offer under an Agreement and Plan of Merger with MannKind Corporation. A series of Company Options with exercise prices below $5.35 were cancelled and converted into a cash payment equal to the per‑share spread between $5.35 and each option's exercise price, and into one contingent value right (CVR) per underlying share.
The Form 4 lists five option grants totaling 84,422 underlying shares canceled: strikes of $3.85, $4.11, $4.53, $3.37, and $4.80, with varying expiration dates between 06/18/2029 and 06/03/2035. The filing is administrative evidence of the merger consideration mechanics for option holders: immediate cash for intrinsic value and CVRs for additional contingent consideration.
scPharmaceuticals insider report: A director, Frederick M. Hudson, filed a Form 4 reporting cancellation/conversion of outstanding company stock options in connection with a merger. On 10/07/2025 options with exercise prices below $5.35 were cancelled and converted into cash consideration equal to the excess of $5.35 over each option's exercise price, plus one contingent value right (CVR) per underlying share. The filing lists four cancelled option grants totaling 72,174 underlying shares (30,000; 19,750; 16,300; 6,124) with exercise prices of $3.85, $4.11, $4.53 and $3.37, and expiration dates ranging from 06/18/2029 to 06/03/2035. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
scPharmaceuticals Inc. reporting person Rachael Nokes (CFO and Treasurer) reported transactions tied to a merger with MannKind Corporation. On 10/07/2025 a tender offer and subsequent merger completed under a Merger Agreement that provided $5.35 per share in cash plus one non-tradable contingent value right (CVR) per share, with CVRs eligible for up to $1.00 aggregate upon certain milestones.
As a result, 30,386 directly held common shares were disposed and 125,675 other common shares (including RSUs) were surrendered for cash and CVRs, leaving 0 shares held following the transactions. Outstanding options with exercise prices below $5.35 were cancelled and cashed out for the excess value, and corresponding RSU awards were converted into cash and CVRs per the agreement.
scPharmaceuticals Inc. completed a merger with MannKind Corporation, effective 10/07/2025, after a Purchaser tender offer that paid $5.35 per share plus one non-tradable contingent value right (CVR) per share representing a potential additional $1.00 payment if a specified milestone is achieved. The reporting person, John H. Tucker (President and CEO and Director), reported disposition of 318,502 shares and a deemed sale/transfer of 122,345 shares on the same date, leaving 0 common shares beneficially owned following the transactions. Time-based RSU awards accelerated, converted into cash at $5.35 per share plus one CVR per share, and in-the-money stock options with exercise prices below $5.35 were cancelled and converted into cash payments equal to the spread plus one CVR per option share.
scPharmaceuticals Inc. (SCPH) reporting person Mette Kirstine Agger, a director, disclosed cancellation and cash-out of certain stock options tied to a merger and tender offer completed on 10/07/2025. Two option grants were disposed: 30,000 options with $3.85 exercise and 19,750 options with $4.11 exercise; both were reported as disposed on 10/07/2025. The filing explains that under the Merger Agreement, options with exercise prices below $5.35 were cancelled and converted into a cash payment equal to the per-share spread times the number of option shares and into one contingent value right (CVR) per option share. The options had expiration dates in 06/03/2035 and 06/11/2034 respectively. The form is a Section 16 disclosure of the changes resulting from the merger terms.
Sara Bonstein, a director of scPharmaceuticals Inc. (SCPH), reported the cancellation on 10/07/2025 of three outstanding stock options totaling 66,050 underlying shares. Each cancelled option was converted under the terms of a Merger Agreement into a cash payment equal to the number of shares covered multiplied by the excess of $5.35 over each option's exercise price, and into one contingent value right (CVR) per share. The cancelled options had exercise prices of $3.85, $4.11, and $4.53 and expiration dates ranging from 06/14/2032 to 06/03/2035
Director Jack A. Khattar reported changes in his holdings following a completed merger transaction. He disposed of 5,000 shares of common stock on 10/07/2025, leaving him with 0 shares of direct common stock. The transactions occurred under a Merger Agreement in which purchasers paid $5.35 per share in cash in a tender offer and issued one non-tradable contingent value right (CVR) per share that may pay up to $1.00 aggregate upon achievement of specified regulatory and net sales milestones. Outstanding company stock options with exercise prices below $5.35 were cancelled and converted into cash payments equal to the excess of $5.35 over the option exercise price, plus one CVR per underlying share; several option grants totaling 72,174 options (aggregate of listed amounts) were reported as disposed/converted.